TY - JOUR
T1 - Neuroendocrine and adrenal tumors, version 2.2021
AU - Shah, Manisha H.
AU - Goldner, Whitney S.
AU - Benson, Al B.
AU - Bergsland, Emily
AU - Blaszkowsky, Lawrence S.
AU - Brock, Pamela
AU - Chan, Jennifer
AU - Das, Satya
AU - Dickson, Paxton V.
AU - Fanta, Paul
AU - Giordano, Thomas
AU - Halfdanarson, Thorvardur R.
AU - Halperin, Daniel
AU - He, Jin
AU - Heaney, Anthony
AU - Heslin, Martin J.
AU - Kandeel, Fouad
AU - Kardan, Arash
AU - Khan, Sajid A.
AU - Kuvshinoff, Boris W.
AU - Lieu, Christopher
AU - Miller, Kimberly
AU - Pillarisetty, Venu G.
AU - Reidy, Diane
AU - Salgado, Sarimar Agosto
AU - Shaheen, Shagufta
AU - Soares, Heloisa P.
AU - Soulen, Michael C.
AU - Strosberg, Jonathan R.
AU - Sussman, Craig R.
AU - Trikalinos, Nikolaos A.
AU - Uboha, Nataliya A.
AU - Vijayvergia, Namrata
AU - Wong, Terence
AU - Lynn, Beth
AU - Hochstetler, Cindy
N1 - Publisher Copyright:
© 2021 Harborside Press. All rights reserved.
PY - 2021/7
Y1 - 2021/7
N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, and multiple endocrine neoplasia. NETs are generally subclassified by site of origin, stage, and histologic characteristics. Appropriate diagnosis and treatment of NETs often involves collaboration between specialists in multiple disciplines, using specific biochemical, radiologic, and surgical methods. Specialists include pathologists, endocrinologists, radiologists (including nuclear medicine specialists), and medical, radiation, and surgical oncologists. These guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine and adrenal tumors and are intended to assist with clinical decision-making. This article is focused on the 2021 NCCN Guidelines principles of genetic risk assessment and counseling and recommendations for well-differentiated grade 3 NETs, poorly differentiated neuroendocrine carcinomas, adrenal tumors, pheochromocytomas, and paragangliomas.
AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, and multiple endocrine neoplasia. NETs are generally subclassified by site of origin, stage, and histologic characteristics. Appropriate diagnosis and treatment of NETs often involves collaboration between specialists in multiple disciplines, using specific biochemical, radiologic, and surgical methods. Specialists include pathologists, endocrinologists, radiologists (including nuclear medicine specialists), and medical, radiation, and surgical oncologists. These guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine and adrenal tumors and are intended to assist with clinical decision-making. This article is focused on the 2021 NCCN Guidelines principles of genetic risk assessment and counseling and recommendations for well-differentiated grade 3 NETs, poorly differentiated neuroendocrine carcinomas, adrenal tumors, pheochromocytomas, and paragangliomas.
UR - http://www.scopus.com/inward/record.url?scp=85112289644&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2021.0032
DO - 10.6004/jnccn.2021.0032
M3 - Article
C2 - 34340212
AN - SCOPUS:85112289644
SN - 1540-1405
VL - 19
SP - 839
EP - 867
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 7
ER -